|Dosage and administration||
Hypersensitivity to etoricoxib or any of the excipients of the product.
|Warnings and precautions for use||
Caution should be exercised with patients with blood clotting disorder, dehydration, patients with a history of heart failure, ischemic heart disease, left ventricular dysfunction, hypertension, and patients with edema due to different reasons.
|Recommendation for pregnancy and breastfeeding||
|Effects on ability to drive and use machines||
Etoricoxib may cause dizziness, headache or drowsiness, which can affect the ability to drive and operate machines.
|Interactions, incompatibilities of medicine||
Warfarin: In patients stabilised on chronic warfarin therapy, the administration of etoricoxib 120mg daily was associated with an approximate 13% increase in prothrombin time International Normalised Ratio (INR). INR values should be frequently monitored prior to initiating or changing the treatment with etoricoxib, especially in the first few days in patients taking warfarin or similar drugs.
|Undesirable effects (ADRs)||
Attention should be paid to the risk of thrombotic cardiovascular events (see Conditions where caution should be taken), some of the following side effects may occur:
|Overdose and management||
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, antipyretic activity. It is an oral potent selective cyclooxygenase-2 (COX-2) inhibitor.
Orally administered etoricoxib is well absorbed. The mean oral bioavailability is approximately 100% and peak plasma concentrations are reached at approximately 1 hour.
|Storage conditions, shelf-life, quality specification of the medicine||
Storage conditions: Protect from humidity and light, below 30 degrees C.
Composition: Each hard capsule contains:
Etoricoxib. . . . . . . . . . . . . . . . . . . . . . . . 500 mg
Cardboard box with 10 blisters of 10 hard capsules.
AGIETOXIB is indicated in adults and adolescents from 16 years old for treatment of acute gouty arthritis (acute gout attack).